KR20150079711A - 글리코시다아제 저해제 및 이의 용도 - Google Patents

글리코시다아제 저해제 및 이의 용도 Download PDF

Info

Publication number
KR20150079711A
KR20150079711A KR1020157013109A KR20157013109A KR20150079711A KR 20150079711 A KR20150079711 A KR 20150079711A KR 1020157013109 A KR1020157013109 A KR 1020157013109A KR 20157013109 A KR20157013109 A KR 20157013109A KR 20150079711 A KR20150079711 A KR 20150079711A
Authority
KR
South Korea
Prior art keywords
tetrahydro
thiopyrano
fluoro
alkyl
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020157013109A
Other languages
English (en)
Korean (ko)
Inventor
라메쉬 카울
어니스트 제이. 맥이천
데이비드 제이. 보카들로
위안시 저우
쿤 당
해럴드 지. 셀닉
Original Assignee
알렉토스 테라퓨틱스 인크.
머크 샤프 앤드 돔 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알렉토스 테라퓨틱스 인크., 머크 샤프 앤드 돔 코포레이션 filed Critical 알렉토스 테라퓨틱스 인크.
Publication of KR20150079711A publication Critical patent/KR20150079711A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
KR1020157013109A 2012-10-31 2013-10-30 글리코시다아제 저해제 및 이의 용도 Ceased KR20150079711A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720708P 2012-10-31 2012-10-31
US61/720,708 2012-10-31
PCT/CA2013/050822 WO2014067003A1 (en) 2012-10-31 2013-10-30 Glycosidase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
KR20150079711A true KR20150079711A (ko) 2015-07-08

Family

ID=50626257

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157013109A Ceased KR20150079711A (ko) 2012-10-31 2013-10-30 글리코시다아제 저해제 및 이의 용도

Country Status (10)

Country Link
US (1) US9695197B2 (https=)
EP (1) EP2914604A4 (https=)
JP (2) JP2015534991A (https=)
KR (1) KR20150079711A (https=)
CN (1) CN104837845B (https=)
AU (1) AU2013337570B2 (https=)
BR (1) BR112015009638A2 (https=)
CA (1) CA2890115A1 (https=)
RU (1) RU2672873C2 (https=)
WO (1) WO2014067003A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180205B2 (en) 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
DK2655388T3 (en) 2010-12-23 2016-09-19 Alectos Therapeutics Inc Selective glykosidaseinhibitorer and uses thereof
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
CN103889996B (zh) 2011-06-27 2016-02-03 阿列科托斯治疗有限公司 选择性糖苷酶抑制剂及其用途
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
EP3966199B1 (en) * 2019-05-10 2026-03-18 Alectos Therapeutics Inc. Non-lysosomal glucosylceramidase inhibitors and uses thereof
WO2024083820A1 (en) 2022-10-18 2024-04-25 Institut National de la Santé et de la Recherche Médicale Method and composition for determining the level of o-glcnacylation in horses

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS423500Y1 (https=) 1964-02-29 1967-03-01
DE2632243C3 (de) 1976-07-17 1979-08-30 Heidelberger Druckmaschinen Ag, 6900 Heidelberg Auf variable Bogenlängen einstellbare Umführtrommel für Druckmaschinen
SU703531A1 (ru) * 1977-09-02 1979-12-15 Институт Химии Нефти И Природных Солей Ан Казахской Сср Способ получени изоксазолинов, конденсированных с гетероциклическими соединени ми
DE3620645A1 (de) 1985-12-20 1987-07-02 Bayer Ag 3-amino-4,5-dihydroxypiperidine, verfahren zu ihrer herstellung und ihre verwendung
JPS6461459A (en) 1987-08-28 1989-03-08 Nippon Shinyaku Co Ltd Moranoline derivative
JPH01180894A (ja) 1988-01-07 1989-07-18 Wako Pure Chem Ind Ltd アミノ糖誘導体の新規な製造法
GB8900719D0 (en) 1989-01-13 1989-03-08 Nycomed As Compounds
US5079254A (en) 1990-06-04 1992-01-07 Merrell Dow Pharmaceuticals Inc. Derivatives of 6-aminooctahydroindolizinetriol
WO1992003415A1 (en) 1990-08-14 1992-03-05 Nova Pharmaceutical Corporation Protein kinase c modulators
US5276120A (en) 1991-05-30 1994-01-04 The Scripps Research Institute Process for forming omega-deuxy-azasugars
US6291657B1 (en) 1993-05-13 2001-09-18 Monsanto Company Deoxygalactonojirimycin derivatives
US5451679A (en) 1994-03-08 1995-09-19 G. D. Searle & Co. 2-chloro and 2-bromo derivatives of 1,5-iminosugars
JPH07316178A (ja) 1994-05-25 1995-12-05 Sankyo Co Ltd 糖アミノオキサゾリン類
CN1131672A (zh) 1994-11-22 1996-09-25 生化学工业株式会社 氨基环戊烷衍生物
CA2235415A1 (en) 1995-09-08 1997-03-13 Novo Nordisk A/S 2-alkylpyrrolidines
CZ120398A3 (cs) 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty
JPH09132585A (ja) 1995-11-10 1997-05-20 Shin Etsu Chem Co Ltd 新規アミノ糖及びキトオリゴ糖又はその類似オリゴ糖の製造方法
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
JPH11349541A (ja) 1998-06-08 1999-12-21 Sankyo Co Ltd アロサミゾリン誘導体の新規な中間体
GB9818732D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collection of compounds
WO2000068194A1 (en) 1999-05-11 2000-11-16 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
US6774140B1 (en) 1999-05-11 2004-08-10 The Scripps Research Institute Iminocyclitol inhibitors of hexoaminidase and glycosidase
FR2817472B1 (fr) 2000-12-06 2003-01-03 Oreal Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre
JP4233262B2 (ja) 2001-03-14 2009-03-04 生化学工業株式会社 カルバ糖アミン誘導体及びそれを用いるグリコシダーゼ阻害剤
WO2002072860A1 (en) 2001-03-14 2002-09-19 Denki Kagaku Kogyo Kabushiki Kaisha Process for producing hyaluronic acid or its derivative
JP4363183B2 (ja) 2001-06-08 2009-11-11 三菱化学株式会社 アザ糖化合物
JP4866515B2 (ja) 2001-07-02 2012-02-01 生化学工業株式会社 糖オキサゾリン誘導体の製造方法
JP2006508014A (ja) 2001-07-24 2006-03-09 イエール・ユニバーシテイ キチナーゼおよびキチナーゼ様分子、ならびに炎症性疾患に関する方法、組成物およびキット
EP1633356A1 (en) 2003-05-22 2006-03-15 The Hospital for Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
CN1548053A (zh) 2003-05-23 2004-11-24 华晶基因技术有限公司 黄芩甙作为治疗焦虑症的药物的新用途
EP1664030A1 (en) 2003-09-16 2006-06-07 AstraZeneca AB Quinazoline derivatives
CA2553866A1 (en) 2004-01-20 2005-08-11 The Scripps Research Institute Treatment of degenerative cartilage conditions in a mammal with glycosi dase inhibitors
US20080166323A1 (en) 2004-04-14 2008-07-10 Uab Research Foundation Activators of Hexosamine Biosynthesis as Inhibitors of Injury Induced by Ischemia or Hermorrhagic Shock
TW200602314A (en) 2004-05-28 2006-01-16 Tanabe Seiyaku Co A novel pyrrolidine compound and a process for preparing the same
EP1773812A1 (en) 2004-07-23 2007-04-18 Bayer CropScience S.A. 3-pyridinylethylcarboxamide derivatives as fungicides
JP4023500B2 (ja) 2004-08-03 2007-12-19 ソニー株式会社 イヤホンアンテナ
AU2005284904A1 (en) 2004-09-13 2006-03-23 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7884115B2 (en) 2004-09-28 2011-02-08 Allergan, Inc. Methods and compositions for the treatment of pain and other neurological conditions
AU2006220187B2 (en) 2005-03-01 2012-11-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AT502145B1 (de) 2005-03-24 2012-01-15 Univ Graz Tech Glycosidase-hemmendes iminoalditol
US7820699B2 (en) 2005-04-27 2010-10-26 Hoffmann-La Roche Inc. Cyclic amines
RU2008120619A (ru) 2005-10-26 2009-12-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) (гетеро)арилы, обладающие антагонистической активностью по отношению к меланинконцентрирующему гормону
US7919521B2 (en) 2005-12-05 2011-04-05 Academia Sinica Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics
EP2057171A4 (en) 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
CN107253970A (zh) 2006-08-31 2017-10-17 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
US8258307B2 (en) 2006-11-07 2012-09-04 University Of Tokyo Amide compound or salt thereof, and biofilm inhibitor, biofilm remover and disinfectant containing the same
EP2321289A4 (en) 2008-08-01 2011-11-16 Univ Fraser Simon SELECTIVE GLYCOSIDASE HEMMER AND ITS USE
CA2732335A1 (en) 2008-08-01 2010-02-04 Simon Fraser University Selective glycosidase inhibitors and uses thereof
EP2323651A2 (en) 2008-08-05 2011-05-25 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
CA2737267A1 (en) 2008-09-16 2010-04-08 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
AT507745B1 (de) 2008-12-16 2012-01-15 Forschungsholding Tu Graz Gmbh Fluorophile glykosidasehemmer
WO2011060397A1 (en) 2009-11-16 2011-05-19 Schering Corporation Substituted amino heterocycles useful as hiv antagonists
EP2566876A4 (en) * 2010-05-06 2014-01-08 Univ Fraser Simon METHOD AND COMPOUNDS FOR INHIBITING GLYCOSYL TRANSFERASES
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) * 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
TW201249848A (en) * 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
WO2012061971A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US8933040B2 (en) 2010-11-08 2015-01-13 Craig A. Coburn Selective glycosidase inhibitors and uses thereof
DK2655388T3 (en) * 2010-12-23 2016-09-19 Alectos Therapeutics Inc Selective glykosidaseinhibitorer and uses thereof
GB201103526D0 (en) 2011-03-02 2011-04-13 Summit Corp Plc Selective glycosidase inhibitors and uses thereof
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012129802A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
CN103889996B (zh) 2011-06-27 2016-02-03 阿列科托斯治疗有限公司 选择性糖苷酶抑制剂及其用途
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
EP2744338B1 (en) 2011-08-18 2016-04-27 Merck Sharp & Dohme Corp. Selective glycosidase inhibitors and uses thereof
AU2012298949B2 (en) 2011-08-25 2016-09-22 Merck Patent Gmbh Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors
KR102108586B1 (ko) 2012-05-08 2020-05-07 머크 샤프 앤드 돔 코포레이션 투과성 글리코시다제 억제제 및 그의 용도
WO2014032184A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
US9522883B2 (en) 2012-08-31 2016-12-20 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014100934A1 (en) 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12180205B2 (en) 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US12275728B2 (en) 2018-09-19 2025-04-15 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors

Also Published As

Publication number Publication date
WO2014067003A1 (en) 2014-05-08
RU2015120556A (ru) 2016-12-20
AU2013337570A1 (en) 2015-05-14
US20150291620A1 (en) 2015-10-15
CA2890115A1 (en) 2014-05-08
CN104837845B (zh) 2018-08-28
US9695197B2 (en) 2017-07-04
RU2672873C2 (ru) 2018-11-20
EP2914604A4 (en) 2016-07-20
CN104837845A (zh) 2015-08-12
JP2015534991A (ja) 2015-12-07
BR112015009638A2 (pt) 2017-07-04
JP2018172405A (ja) 2018-11-08
EP2914604A1 (en) 2015-09-09
AU2013337570B2 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
KR101979036B1 (ko) 선택적인 글리코시다아제 저해제 및 이의 용도
KR20150079711A (ko) 글리코시다아제 저해제 및 이의 용도
KR102054744B1 (ko) 선택적인 글리코시다아제 저해제 및 이의 용도
EP2935283B1 (en) Glycosidase inhibitors and uses thereof
EP2637503B1 (en) Selective glycosidase inhibitors and uses thereof
US9701693B2 (en) Selective glycosidase inhibitors and uses thereof
EP2890678A1 (en) Glycosidase inhibitors and uses thereof
AU2011349021A1 (en) Selective glycosidase inhibitors and uses thereof
WO2014032184A1 (en) Glycosidase inhibitors and uses thereof
WO2012062157A1 (en) Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors
EP2691407A1 (en) Selective glycosidase inhibitors and uses thereof
EP2890676A1 (en) Glycosidase inhibitors and uses thereof
WO2012129802A1 (en) Pyrano[3,2-d]thiazol derivatives and uses as selective glycosidase inhibitors thereof
HK1191016B (en) Selective glycosidase inhibitors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150519

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20181017

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200427

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200713

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20200427

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I